Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes
Julien Racle, Justine Michaux, Georg Alexander Rockinger, et al.
Nature Biotechnology (2019) Vol. 37, Iss. 11, pp. 1283-1286
Open Access | Times Cited: 255

Showing 26-50 of 255 citing articles:

NNAlign_MA; MHC Peptidome Deconvolution for Accurate MHC Binding Motif Characterization and Improved T-cell Epitope Predictions
Bruno Alvarez, Birkir Reynisson, Carolina Barra, et al.
Molecular & Cellular Proteomics (2019) Vol. 18, Iss. 12, pp. 2459-2477
Open Access | Times Cited: 104
Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation
Zilei Liu, Jie Li, Mingkuan Chen, et al.
Cell (2020) Vol. 183, Iss. 4, pp. 1117-1133.e19
Open Access | Times Cited: 98
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
Vibha Jawa, Frances Terry, Jochem Gokemeijer, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 97
Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide
Rodrigo Barquera, Evelyn Collen, Da Di, et al.
HLA (2020) Vol. 96, Iss. 3, pp. 277-298
Open Access | Times Cited: 94
Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence
Ying Xu, Guan-Hua Su, Ding Ma, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 86
Artificial intelligence in early drug discovery enabling precision medicine
Fabio Boniolo, Emilio Dorigatti, Alexander J. Ohnmacht, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 9, pp. 991-1007
Open Access | Times Cited: 78
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives
Xiaotong Chen, Ju Yang, Lifeng Wang, et al.
Theranostics (2020) Vol. 10, Iss. 13, pp. 6011-6023
Open Access | Times Cited: 75
Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19
Gunjan Arora, Jayadev Joshi, Rahul Shubhra Mandal, et al.
Pathogens (2021) Vol. 10, Iss. 8, pp. 1048-1048
Open Access | Times Cited: 73
DLpTCR: an ensemble deep learning framework for predicting immunogenic peptide recognized by T cell receptor
Zhaochun Xu, Meng Luo, Wei‐Zhong Lin, et al.
Briefings in Bioinformatics (2021) Vol. 22, Iss. 6
Closed Access | Times Cited: 73
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
Jan A. Rath, Caroline Arber
Cells (2020) Vol. 9, Iss. 6, pp. 1485-1485
Open Access | Times Cited: 72
Gene fusion neoantigens: Emerging targets for cancer immunotherapy
Yue Wang, Tao Shi, Xueru Song, et al.
Cancer Letters (2021) Vol. 506, pp. 45-54
Closed Access | Times Cited: 64
The 2022 Report on the Human Proteome from the HUPO Human Proteome Project
Gilbert S. Omenn, Lydie Lane, Christopher M. Overall, et al.
Journal of Proteome Research (2022) Vol. 22, Iss. 4, pp. 1024-1042
Open Access | Times Cited: 46
The MHC Motif Atlas: a database of MHC binding specificities and ligands
Daniel M. Tadros, Simon Eggenschwiler, Julien Racle, et al.
Nucleic Acids Research (2022) Vol. 51, Iss. D1, pp. D428-D437
Open Access | Times Cited: 44
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation
Elizabeth S. Borden, Kenneth H. Buetow, Melissa A. Wilson, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 42
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
Myriam Ben Khelil, Yann Godet, Syrine Abdeljaoued, et al.
Cancers (2022) Vol. 14, Iss. 1, pp. 260-260
Open Access | Times Cited: 41
Accurate MHC Motif Deconvolution of Immunopeptidomics Data Reveals a Significant Contribution of DRB3, 4 and 5 to the Total DR Immunopeptidome
Saghar Kaabinejadian, Carolina Barra, Bruno Alvarez, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond
Simona Pagliuca, Carmelo Gurnari, Marie Thérèse Rubio, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning
Jonas Birkelund Nilsson, Saghar Kaabinejadian, Hooman Yari, et al.
Science Advances (2023) Vol. 9, Iss. 47
Open Access | Times Cited: 38
Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues
Jennifer G. Abelin, Erik J. Bergstrom, Keith Rivera, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 35
Machine learning reveals limited contribution of trans-only encoded variants to the HLA-DQ immunopeptidome
Jonas Birkelund Nilsson, Saghar Kaabinejadian, Hooman Yari, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 25
Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy
Zhe Zhang, Xiawei Wei
Seminars in Cancer Biology (2023) Vol. 90, pp. 57-72
Closed Access | Times Cited: 24
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Zhaokai Zhou, Jiahui Wang, Jiaojiao Wang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Michal Bassani‐Sternberg, Antonia Digklia, Florian Huber, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 63
CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
Jennifer R. Richardson, Anna Schöllhorn, Cécile Gouttefangeas, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 596-596
Open Access | Times Cited: 43
The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies
Jonas P. Becker, Angelika B. Riemer
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36

Scroll to top